What is claimed is:

1. A compound comprising Formula I:



I

wherein:

G^1 is selected from the group consisting of **a**, **b^1**,and **b^2**



a **b^1** **b^2**

A is selected from the group consisting of phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, and thienyl, all optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, $-SO_2R'$, $-NR'SO_2R''$, $-SO_2NR'R''$, $-NR'R''$, or $-COR'$;

R' and R" are each independently hydrogen or lower alkyl;

G^2 is selected from the group represented by the Formula **c**, **d**, **e**, and **f**



c **d** **e** **f**

R^1 and R^2 are independently in each occurrence selected from the group consisting of hydrogen, lower alkyl, halogen, haloalkyl, $-NR'R''$, $-OR'$, $-NR'SO_2R''$, $-SO_2R'$, $-SO_2NR'R''$, $-COR'$, cyano, nitro, phenyl (optionally

substituted with halogen, alkyl, cyano, nitro, or alkoxy), or heteroaryl (optionally substituted with halogen, alkyl, cyano, nitro or alkoxy); and wherein R' and R" are as defined hereinbefore;

R^1 and R^2, if adjacent, taken together with the carbons to which they are attached may also form an aromatic ring, optionally substituted with one or two substitutents selected from the group consisting of lower alkyl, halogen, cyano, and lower alkoxy; and

n is an integer selected from 0, 1, 2, and 3;

or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof.

2. The compound of Claim 1, wherein G^2 is selected from the group represented by the Formula **c** and **d**.

3. The compound of Claim 1, wherein G^2 is selected from the group represented by the Formula **e** and **f**.

4. The compound of Claim 1, wherein G^1 is selected from the group represented by the Formula **a**.

5. The compound of Claim 4, wherein G^2 is selected from the group represented by the Formula **c** and **d**.

6. The compound of Claim 5, wherein A is phenyl optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, $-SO_2R'$, $-NR'SO_2R"$, $-SO_2NR'R"$, $-COR'$, and $-NR'R"$, and R' and R" are each independently hydrogen or lower alkyl.

7. The compound of Claim 6, wherein G^2 is a group represented by the Formula **c**.

8. The compound of Claim 7, wherein R^1 is selected from the group consisting of hydrogen, lower alkyl, halogen, cyano, nitro, $-OR'$, $-SO_2R'$, $-NR'SO_2R"$, $-COR'$, and $-NR'R"$, and R' and R" are each independently hydrogen or lower alkyl.

9. The compound of Claim 7, wherein R^1 is phenyl, which is optionally substituted with halogen, lower alkyl, cyano, nitro or alkoxy.

10. The compound of Claim 7, wherein R^1 is pyridinyl which is optionally substituted with halogen, lower alkyl, cyano, nitro or alkoxy.

11. The compound of Claim 7, wherein R^1 is thienyl, which is optionally substituted with halogen, lower alkyl, cyano, nitro or alkoxy.

12. The compound of Claim 7, wherein R^1 and R^2, if adjacent, taken together with the carbons to which they are attached form an aromatic ring, which is optionally substituted with halogen, lower alkyl, cyano, nitro or alkoxy.

13. The compound of Claim 5, wherein G^2 is a group represented by the Formula **c** and A is pyridinyl.

14. The compound of Claim 13, wherein R^1 is selected from the group consisting of hydrogen, lower alkyl, halogen, cyano, nitro, -OR', $-SO_2R'$, $-NR'SO_2R''$, -COR', and -NR'R", and R' and R" are each independently hydrogen or lower alkyl.

15. The compound of Claim 13, wherein R^1 is phenyl optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, $-SO_2R'$, $-NR'SO_2R''$, $-SO_2NR'R''$, -NR'R", or -COR', and R' and R" are each independently hydrogen or lower alkyl.

16. The compound of Claim 5, wherein G^2 is a group represented by the Formula **c** and A is pyridiminyl, which is optionally substituted with halogen, alkyl, cyano, nitro, or alkoxy.

17. The compound of Claim 16, wherein R^1 is selected from the group consisting of hydrogen, lower alkyl, halogen, cyano, nitro, -OR', $-SO_2R'$, $-NR'SO_2R''$, -COR', and -NR'R", and R' and R" are each independently hydrogen or lower alkyl.

18. The compound of Claim 4, wherein G^2 is a group represented by the Formula **e** .

19. The compound of Claim 18, wherein A is phenyl optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, $-SO_2R'$, $-NR'SO_2R''$, $-SO_2NR'R''$, -NR'R", or -COR', R^1 is selected from the group consisting of hydrogen, lower alkyl, halogen, cyano, nitro, -OR', $-SO_2R'$, $-NR'SO_2R''$, -

COR', and -NR'R", and R' and R" are each independently hydrogen or lower alkyl.

20. The compound of Claim 18, wherein A is phenyl optionally substituted lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, -SO_2R', -NR'SO_2R", -SO_2NR'R", -NR'R", or -COR'; R' and R" are each independently hydrogen or lower alkyl; and R^1 is phenyl optionally substituted with halogen, alkyl, cyano, nitro, or alkoxy.

21. The compound of Claim 1, wherein G^1 is a group represented by the Formula **b**^{1}.

22. The compound of Claim 21, wherein G^2 is a group represented by the Formula **c**.

23. The compound of Claim 22, wherein A is phenyl optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, -SO_2R', -NR'SO_2R", -SO_2NR'R", -NR'R", or -COR'; and R' and R" are each independently hydrogen or lower alkyl.

24. The compound of Claim 23, wherein R^1 is selected from the group consisting of hydrogen, lower alkyl, halogen, cyano, nitro, -OR', -SO_2R', -NR'SO_2R", -COR', and -NR'R", and R' and R" are each independently hydrogen or lower alkyl.

25. The compound of Claim 1, wherein G^1 is selected from the group represented by Formula **b**^{2}.

26. The compound of Claim 25, wherein G^2 is selected from the group represented by the Formula **c**.

27. The compound of Claim 26, wherein A is phenyl optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, -SO_2R', -NR'SO_2R", -SO_2NR'R", -NR'R", or -COR'; and R' and R" are each independently hydrogen or lower alkyl.

28. The compound of Claim 27, wherein R^1 is selected from the group consisting of hydrogen, lower alkyl, halogen, cyano, nitro, -OR', -SO_2R', -NR'SO_2R", -COR', and -NR'R", and R' and R" are each independently hydrogen or lower alkyl.

29. The compound of Claim 1, wherein the compound is selected from the group consisting of:

4-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-biphenyl-3-carboxylic acid;

4'-fluoro-4-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-biphenyl-3-carboxylic acid;

4'-fluoro-4-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-biphenyl-3-carboxylic acid;

2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-naphthalene-1-carboxylic acid;

2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-5-isopropoxy-benzoic acid;

2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-6-methyl-benzoic acid;

2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-5-pyridin-3-yl-benzoic acid;

5-methanesulfonyl-2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-benzoic acid;

4-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-biphenyl-3-carboxylic acid;

2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-5-thiophen-3-yl-benzoic acid;

5-bromo-2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-benzoic acid;

[3-(1*H*-tetrazol-5-yl)-biphenyl-4-yl]-carbamic acid 5-phenyl-benzofuran-2-ylmethyl ester;

[2-(1*H*-tetrazol-5-yl)-phenyl]-carbamic acid 5-phenyl-benzofuran-2-ylmethyl ester;

2-chloro-6-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-benzoic acid;

2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-naphthalene-1-carboxylic acid;

2-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-5-methanesulfonylamino-benzoic acid;

[2-(5-phenyl-benzofuran-2-ylmethoxycarbonylamino)-phenyl]-acetic acid;

2-[2-(biphenyl-4-yloxy)-ethoxycarbonylamino]-6-chloro-benzoic acid; and

2-chloro-6-(5-pyrimidin-5-yl-benzofuran-2-ylmethoxycarbonylamino)-benzoic acid.

30. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in admixture with at last one pharmaceutically acceptable carrier.

31. A method of treating a subject with a disease state that is alleviated with an IP antagonist, with an effective amount of one of more compounds of Claim 1.

32. The method of treatment of Claim 31, wherein the disease state comprises disorders of the urinary tract, pain, inflammation, respiratory states, edema formation or hypotensive vascular diseases.

33. The method of treatment of Claim 32, wherein the disease state comprises bladder disorders associated with bladder outlet obstruction and urinary incontinence conditions.

34. The method of treatment of Claim 32, wherein the disease state comprises pain.

35. The method of treatment of Claim 32, wherein the disease state comprises inflammation.

36. The method of treatment of Claim 32, wherein the disease state comprises respiratory states form allergies and asthma.

37. A process for preparing a compound as claimed in Claim 1, which process comprises:

esterification of the compounds having a general Formula **2** or **3**:



2 3

wherein n, R^1 and R^2 are as defined in Claim 1,

acylation with phosgene, followed by reaction with a compound of general Formula **1**



1

wherein G^1 is as defined in Claim 1,

and hydrolysis, to provide a compound of the general Formula **Ia** or **Ib**



wherein n, G^1, R^1, and R^2 are as defined in Claim 1.

38. A process for preparing a compound as claimed in Claim 1, which process comprises:

acylation with phosgene of a compound of general Formula **cm** or **co**,



wherein n, R^1 and R^2 are as defined herein,

followed by reaction with a compound of general Formula **1**



1

wherein G^1 is as defined in Claim 1,

and treatment with azide to provide a compound of general Formula **Ic** or **Id**



Ic

or



Id

wherein n, G^1, R^1, and R^2 are as defined in Claim 1.